Form 4: Arcus Biosciences COO Sells Shares for Tax Obligations

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold shares to cover tax withholding obligations related to RSU vesting, not as a discretionary trade.

Summary

• Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, Inc. (RCUS), reported sales of common stock.
• On December 16, 2025, 11,225 shares were sold at a weighted average price of $21.8843 per share.
• On December 17, 2025, an additional 9,983 shares were sold at a weighted average price of $22.1595 per share.
• These sales were non-discretionary, executed automatically by the issuer to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units (RSUs).
• The automatic sales were conducted pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025.
• Following these transactions, Jennifer Jarrett beneficially owns 193,024 shares of common stock, which includes the unvested portion of her RSU grants.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations related to RSU vesting, which is a neutral event for the company's stock and does not indicate a change in management's outlook or company fundamentals.

Future Outlook

NA

Management Comments

• The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.

Industry Context

Routine insider transactions for tax withholding purposes are common across all industries for executives receiving equity compensation and do not typically reflect specific industry trends or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: Disclosure of routine insider stock sales for tax purposes, which are non-discretionary and generally not indicative of management's view on future stock performance, thus having minimal direct impact.
• Employees: The transaction reflects a standard process for managing equity compensation and tax obligations, which is common for employees receiving RSUs.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by a company officer to cover tax withholding obligations related to RSU vesting. This type of transaction is common and does not reflect a discretionary investment decision by the insider, thus it typically has no material impact on the company's fundamental outlook or stock valuation. Therefore, it does not warrant a change in investment recommendation.

Keywords

Arcus Biosciences, RCUS, Insider Transaction, Form 4, Stock Sale, RSU Vesting, Tax Withholding, Jennifer Jarrett, Chief Operating Officer